Indaptus Therapeutics Announces Clinical Supply Agreement With BeiGene To Evaluate Novel Cancer Treatment Combinations
Portfolio Pulse from Benzinga Newsdesk
Indaptus Therapeutics has announced a clinical supply agreement with BeiGene to evaluate a novel cancer treatment combining BeiGene's tislelizumab and Indaptus' Decoy20. The trial is expected to start in 2025, with a conference call scheduled for October 22, 2024.
October 22, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BeiGene has partnered with Indaptus Therapeutics to evaluate a new cancer treatment combining its PD-1 inhibitor, tislelizumab, with Indaptus' Decoy20. This collaboration could strengthen BeiGene's position in the immunotherapy market.
The collaboration with Indaptus to test tislelizumab in a novel combination could enhance BeiGene's product offerings and market position in cancer immunotherapy, potentially leading to positive investor sentiment.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 80
POSITIVE IMPACT
Indaptus Therapeutics has entered a clinical supply agreement with BeiGene to test a combination of its Decoy20 with BeiGene's tislelizumab. This partnership could enhance Indaptus' position in cancer treatment innovation.
The agreement with BeiGene to test a novel cancer treatment combination could significantly impact Indaptus' future prospects, potentially leading to successful clinical outcomes and increased investor interest.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90